Anna Shoko Nishiya

Dr. Anna Shoko Nishiya

Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, Brazil
+1
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Science
Verified
Journal Article
Open access
PDF file
LBLewis Fletcher Buss
Lewis Fletcher Buss
CJCarlos Augusto Prete Jr.
Carlos Augusto Prete Jr.
CAClaudia M. M. Abrahim
Claudia M. M. Abrahim
AMAlfredo Mendrone
Alfredo Mendrone
TSTassila Salomon
Tassila Salomon
ESEster Cerdeira Sabino
Ester Cerdeira Sabino
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230

25 January 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
AMAlfredo Mendrone‐Junior
Alfredo Mendrone‐Junior
CDCarla Luana Dinardo
Carla Luana Dinardo
SFSuzete Cleuza Ferreira
Suzete Cleuza Ferreira
ANAnna Shoko Nishiya
Anna Shoko Nishiya
NSNanci Alves Salles
Nanci Alves Salles
ESEster Cerdeira Sabino
Ester Cerdeira Sabino

21 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ANAnna Shoko Nishiya
Anna Shoko Nishiya
CACesar de Almeida-Neto
Cesar de Almeida-Neto
SFSuzete C. Ferreira
Suzete C. Ferreira
CACecília S. Alencar
Cecília S. Alencar
CDClaudia Di-Lorenzo-Oliveira
Claudia Di-Lorenzo-Oliveira
ESEster C. Sabino
Ester C. Sabino
Hepatitis C virus (HCV) infection is a global health problem estimated to affect almost 200 million people worldwide. The aim of this study is to analyze the subtypes and existence of variants resistant to protease inhibitors and their association with potential HCV risk factors among blood donors in Brazil. Repeat anti-HCV reactive blood donors are systematically asked to return for retest, notification, and counseling in which they are interviewed for risk factors for transfusion-transmitted diseases. We analyzed 202 donors who returned for counseling from 2007 to 2010 and presented enzyme immunoassay- and immunoblot-reactive results. The HCV genotypes and resistance mutation analyses were determined by the direct sequencing of the NS5b and NS3 regions, respectively. The HCV viral load was determined using an in-house real-time PCR assay targeting the 5′-NCR. HCV subtypes 1b, 1a, and 3a were found in 45.5%, 32.0%, and 18.0% of the donors, respectively. The mean viral load of genotype 1 was significantly higher than that of the genotype 3 isolates. Subtype 1a was more frequent among young donors and 3a was more frequent among older donors. Protease inhibitor-resistant variants were detected in 12.8% of the sequenced samples belonging to genotype 1, and a higher frequency was observed among subtype 1a (20%) in comparison to 1b (8%). There was no difference in the prevalence of HCV risk factors among the genotypes or drug-resistant variants. We found a predominance of subtype 1b, with an increase in the frequency of subtype 1a, in young subjects. Mutations conferring resistance to NS3 inhibitors were frequent in treatment-naïve blood donors, particularly those infected with subtype 1a. These variants were detected in the major viral population of HCV quasispecies, have replicative capacities comparable to nonresistant strains, and could be important for predicting the response to antiviral triple therapy.

11 July 2011 in Virology Journal
Verified
Journal Article
Open access
PDF file
MAMónica V Alvarado-Mora
Mónica V Alvarado-Mora
LBLivia Botelho
Livia Botelho
ANAnna Shoko Nishiya
Anna Shoko Nishiya
RNRaymundo A Neto
Raymundo A Neto
MGMichele S Gomes-Gouvea
Michele S Gomes-Gouvea
João Renato Rebello PinhoJoão Renato Rebello Pinho
João Renato Rebello Pinho
GB virus C (GBV-C) is an enveloped positive-sense ssRNA virus belonging to the Flaviviridae family. Studies on the genetic variability of the GBV-C reveals the existence of six genotypes: genotype 1 predominates in West Africa, genotype 2 in Europe and America, genotype 3 in Asia, genotype 4 in Southwest Asia, genotype 5 in South Africa and genotype 6 in Indonesia. The aim of this study was to determine the frequency and genotypic distribution of GBV-C in the Colombian population.

1 January 2021 in Clinics
Verified
Journal Article
Open access
LNLauro Vieira Perdigão Neto
Lauro Vieira Perdigão Neto
MMMicheli Medeiros
Micheli Medeiros
SLSuzete Cleusa Ferreira Spina Lombardi
Suzete Cleusa Ferreira Spina Lombardi
ANAnna Shoko Nishiya
Anna Shoko Nishiya
DADenise Brandão de Assis
Denise Brandão de Assis
ALAnna S. Levin
Anna S. Levin
Bacterial and aseptic meningitis after neurosurgery can present similar clinical signs and symptoms. The aims of this study were to develop and test a molecular method to diagnose bacterial meningitis (BM) after neurosurgery.A 16S ribosomal RNA gene PCR-based ...

10 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAline S Bossa
Aline S Bossa
VSVera M C Salemi
Vera M C Salemi
SRSusan P Ribeiro
Susan P Ribeiro
DRDerval dos Santos Rosa
Derval dos Santos Rosa
RFRodrigues Ferreira
Rodrigues Ferreira
ECEdecio Cunha-Neto
Edecio Cunha-Neto
The participation of immune/inflammatory mechanisms in the pathogenesis of tropical endomyocardial fibrosis (EMF) has been suggested by the finding of early blood and myocardial eosinophilia. However, the inflammatory activation status of late-stage EMF patients is still unknown. We evaluated pro- and anti-inflammatory cytokine levels in plasma samples from late stage EMF patients. Cytokine levels of Tumor Necrosis Factor (TNF)-α, Interferon (IFN)-γ, Interleukin (IL)-2, IL-4, IL-6, and IL-10 were assayed in plasma samples from 27 EMF patients and compared with those of healthy control subjects. All EMF patients displayed detectable plasma levels of at least one of the cytokines tested. We found that TNF-α, IL-6, IL-4, and IL-10 were each detected in at least 74% of tested sera, and plasma levels of IL-10, IL-4, and TNF-α were significantly higher than those of controls. Plasma levels of such cytokines positively correlated with each other. The mixed pro- and anti-inflammatory/Th2circulating cytokine profile in EMF is consistent with the presence of a persistent inflammatory stimulus. On the other hand, the detection of increased levels of TNF-α may be secondary to the cardiovascular involvement observed in these patients, whereas IL-4 and IL-10 may have been upregulated as a homeostatic mechanism to buffer both production and deleterious cardiovascular effects of pro-inflammatory cytokines. Further studies might establish whether these findings play a role in disease pathogenesis.